Preclinical assessment of ulixertinib, a novel ERK1/2 inhibitor

• मुख्य लेखकों: Vinod Anera Balakrishna (लेखक), Anitha Police (लेखक), Rakesh Hiremath (लेखक), Anusha Raj (लेखक), Suresh P Sulochana (लेखक), Devaraj V Chandrasekhar (लेखक), Zainuddin Mohd (लेखक), Ravi Kanth Bhamidipati (लेखक), Ramesh Mullangi (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: International Association of Physical Chemists (IAPC), 2017-12-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Ulixertinib (BVD-523) is a novel and selective reversible inhibitor of ERK1/ERK2. In xenograft studies it inhibited tumor growth in BRAF-mutant melanoma and colorectal xenografts as well as KRAS-mutant colorectal and pancreatic models. Ulixertinib is currently in Phase I clinical development for the...